Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 814

recruiting
3 961
countries
28
conditions
2 101

10 273 trials match your criteria

Cholangiocarcinoma+3

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Hormone receptor positive HER2 negative breast cancer

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant

Cardiac amyloidosis

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid Bp

Parkinson's disease

Not recruiting
Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:5,7-Dimethyl-N-((1R,4R)-4-(Pentyloxy)Cyclohexyl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide

Sepsis

Not recruiting
Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Teicoplanin

COVID-19+2

Not recruiting
Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus

Kidney transplant rejection

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase

Tourette's disorder

Not recruiting
Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years
  • Substances:Ecopipam Hydrochloride

Study on the Safety and Effectiveness of THE-630 for Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:The-630

Study of Pembrolizumab with Chemotherapy for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Carboplatin

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.